Search

Displaying results 2951 - 2960 of 10000 in total
  1. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. … [label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen].

    Synonyms: 4-(6-Methoxy-2-naphthalenyl)-2-butanone, 4-(6-Methoxy-2-naphthyl)-2-butanoneMixtures: NuDroxiPAK N-500
  2. Drug

    Fosinopril

    go.drugbank.com/drugs/DB00492
    ApprovedInvestigational

    It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). … ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS).

    Mixtures: MONOPRIL PLUS 10 MG/12.5 MG TABLET, 28 ADET, MONOPRIL PLUS 20 MG/12.5 MG TABLET, 28 ADETProducts: SIMIPRIL® 10 MG TABLETAS, ACEFOR 10 MG TABLET, 28 ADET
  3. Drug

    Anidulafungin

    go.drugbank.com/drugs/DB00362
    Approved

    There is preliminary evidence that it has a similar safety profile to caspofungin. … Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366.

    Products: ANIDULAFUNGINA EG, DULAFUX 50 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 1 ADET
  4. Drug

    Fluvoxamine

    go.drugbank.com/drugs/DB00176
    ApprovedInvestigational

    It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. … Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: FLUVOXAMINA EG, FAVERIN 50 MG
  5. Drug

    Repaglinide

    go.drugbank.com/drugs/DB00912
    ApprovedInvestigational

    In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control … Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.

    Mixtures: PAREGLIN 1 MG/500 MG FILM KAPLI TABLET, 90 ADET, REPAMEF 1/1000 MG EFERVESAN TABLET, 30 ADETCategories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 Substrates
  6. Drug

    Gemifloxacin

    go.drugbank.com/drugs/DB01155
    ApprovedInvestigational

    Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. … It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.

    Categories: 4-Quinolones, Heterocyclic Compounds, 2-RingProducts: ONFACT 320 MG FİLM TABLET, 5 ADET, FACTIVE 320 MG FİLM TABLET, 5 ADET
  7. Drug

    Ferric hydroxide

    go.drugbank.com/drugs/DB13423
    Investigational

    Products: FERIFER 100 MG/5 ML ORAL COZELTI ICEREN 10 KASIK, FERIFER-40 ORAL COZELTI 40 MG/5 ML KAŞIK, 10 ADET
  8. Drug

    Omega-3 fatty acids

    go.drugbank.com/drugs/DB11133
    ApprovedInvestigationalNutraceutical

    Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon atom from the end of the carbon chain. … Omega-3 fatty acids play a critical role in metabolism and cellular function and they are available as daily supplements. On September 8, 2004, the U.S.

    Synonyms: n-3 PUFAs, n-3 fatty acidsMixtures: LIPOMEGA® 10, Lipidem 200mg/ml Emulsion for Infusion
  9. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    occurs in a pH-dependent manner[A218551] - this allows satralizumab to bind an IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the … [A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased

    Synonyms: Humanised anti-IL-6 receptor monoclonal antibodyCategories: Interleukin-6 Receptor Antagonist
  10. Drug

    Ipratropium

    go.drugbank.com/drugs/DB00332
    ApprovedInvestigational

    [A176939] It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. … Ipratropium is a quaternary ammonium derivative of [atropine][A176957] that acts as an anticholinergic agent.

    Mixtures: SALBUTAMOLO E IPRATROPIO BROMURO EG, NASOVİNE DUO 0,5 MG + 0,6 MG/ML BURUN SPREYİ, ÇÖZELTİ, 1 ADETProducts: ATROVENT 500 MG /2ML, Nasipral 0,3 mg/ml Nasenspray, Lösung